Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Pembrolizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention. Browse Pembrolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
840
Shown on this page
12
Current sort
Recently updated
Therapy scope
Pembrolizumab
Additional filters apply within this therapy.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this therapy

These controls apply only within Pembrolizumab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 769–780 of 840 matching trials for Pembrolizumab.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Open in full search
Active, not recruiting Phase 2 Interventional

SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors

NCT05642780
View directory record Official record
Conditions
Solid Tumor
Interventions
Pembrolizumab, SKB264
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Anderson, Indiana • Louisville, Kentucky • Annapolis, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Aug 1, 2026, 9:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

NCT04370587
View directory record Official record
Conditions
HNSCC, Melanoma, NSCLC, Sarcoma, Solid Tumor, Squamous Cell Carcinoma
Interventions
T3011, T3011 + pembrolizumab
Biological · Combination Product
Lead sponsor
ImmVira Pharma Co. Ltd
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
Gilbert, Arizona • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 15, 2026, 1:45 PM EDT
Active, not recruiting Phase 2 Interventional

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

NCT03383094
View directory record Official record
Conditions
Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Head and Neck Squamous Cell Carcinoma, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Metastatic, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Stage III, Tumor, Tumor Metastasis, Tumor Neck, Tumor Recurrence
Interventions
Cisplatin, Pembrolizumab, Radiation therapy
Drug · Radiation
Lead sponsor
Loren Mell, MD
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
6
States / cities
Tucson, Arizona • La Jolla, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 14, 2026, 8:59 PM EDT
Recruiting Phase 2 Interventional

A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

NCT07207395
View directory record Official record
Conditions
Lung Cancer (NSCLC)
Interventions
JBI-802, Pembrolizumab
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jul 31, 2026, 9:20 AM EDT
Recruiting Phase 1 Interventional

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

NCT04295863
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Nivolumab Extended, Nivolumab Standard, Pembrolizumab Extended, Pembrolizumab Standard
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 18, 2026, 3:57 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

NCT05933577
View directory record Official record
Conditions
Melanoma
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,089 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
34
States / cities
Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Nov 5, 2026, 3:15 AM EST
Active, not recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286
View directory record Official record
Conditions
PD-L1 Positive, Triple Negative Breast Cancer
Interventions
Carboplatin, Gemcitabine, Paclitaxel, Pembrolizumab, Sacituzumab Govitecan-hziy, nab-Paclitaxel
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
247
States / cities
Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 175 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Nov 4, 2026, 4:06 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

NCT03647163
View directory record Official record
Conditions
Neuroendocrine Carcinoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma (RCC), Solid Tumor
Interventions
Pembrolizumab, VSV-IFNβ-NIS, ipilimumab + nivolumab
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Rochester, Minnesota • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 16, 2026, 4:35 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

NCT05845814
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Urothelial Neoplasms
Interventions
Coformulated favezelimab/pembrolizumab, Coformulated vibostolimab/pembrolizumab, EV, Pembrolizumab
Biological · Combination Product
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
La Jolla, California • Orange, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Nov 3, 2026, 8:39 PM EST
Active, not recruiting Phase 1 Interventional

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors

NCT05653882
View directory record Official record
Conditions
Melanoma, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck
Interventions
etakafusp alfa (AB248), pembrolizumab
Biological
Lead sponsor
Asher Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
20
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 28, 2026, 4:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

NCT07158918
View directory record Official record
Conditions
Solid Tumors
Interventions
ABL103, KEYTRUDA® (pembrolizumab), Taxane
Drug
Lead sponsor
ABL Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 22, 2026, 7:48 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

NCT05318573
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer, Advanced Urothelial Carcinoma
Interventions
FF-10832, Pembrolizumab
Drug
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
23
States / cities
Long Beach, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 15, 2026, 10:23 AM EDT

About this Pembrolizumab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pembrolizumab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Pembrolizumab.